General form of registration statement for all companies including face-amount certificate companies

Consolidated Statements of Cash Flows

v3.24.3
Consolidated Statements of Cash Flows - USD ($)
 9 Months Ended 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities:        
Net loss $ (4,308,639) $ (15,155,955) $ (18,832,694) $ (29,721,841)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation 9,633 9,634 12,845 12,845
Acquired in-process research and development 12,000 282,000 282,000 971,477
Amortization of operating lease right-of-use asset 51,876 46,650 62,905 80,412
Share-based compensation 170,795 198,620 248,626 876,368
Financing costs related to ChEF Purchase Agreement 370,426    
Non-cash financing costs 1,732    
Changes in operating assets and liabilities:        
Prepaid expenses and other current assets 623,566 (218,940) (33,653) (454,269)
Incentive tax receivable 266,964 (31,864)    
Other assets (74,274) (155,366) (414,206)
Accounts payable (455,038) (1,877,222) (2,631,215) 971,041
Accrued expenses and other current liabilities (2,034,243) 264,872 231,953 641,372
Income tax receivable     (69,269) (717,305)
Operating lease liability (53,725) (34,609) (51,329) (83,685)
Deferred income (18,626) (110,549) (147,805) (349,943)
Net cash used in operating activities (5,437,553) (16,782,729) (21,341,842) (27,773,528)
Cash flows from investing activities:        
Purchases of in-process research and development (12,000) (273,250) (443,250) (810,227)
Net cash used in investing activities (12,000) (273,250) (443,250) (810,227)
Cash flows from financing activities:        
Proceeds from sale of preferred stock and common stock warrants, net of issuance costs     2,172,649
Proceeds from sale of common stock, net of issuance costs 3,899,157 21,024,070 21,006,371 1,841,918
Payment of deferred offering costs (15,000)    
Payment of financing costs related to ChEF Purchase Agreement (157,500)    
Proceeds from exercise of warrants, net of issuance costs 3,002,968 849 849
Repayments of related party notes (748) (748)
Net cash provided by financing activities 6,729,625 21,024,171 21,006,472 4,014,567
Net decrease in cash 1,280,072 3,968,192 (778,620) (24,569,188)
Cash, beginning of year 2,274,259 3,052,879 3,052,879 27,622,067
Cash, end of year 3,554,331 7,021,071 2,274,259 3,052,879
Supplemental disclosure of non-cash operating, investing and financing activities:        
Net settlement of warrants 75 1,142 52
ChEF Purchase Agreement financing costs in accounts payable 212,926    
In-process research and development in accrued expenses 170,000 161,250
Deferred offering costs charged against proceeds from sale of common stock 32,340 32,340
Issuance of common stock on vesting of restricted stock units 5    
Common stock issuance costs in accounts payable and accrued expenses $ 78,073 78,073
Change in operating lease right-of-use asset and liability due to amended lease     213,793
Deferred offering costs in accounts payable and accrued expenses     $ 49,988 $ 80,940